Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Charles Fong"'
Autor:
Hisham Mehanna, Piers Gaunt, Anthony Kong, Andrew Hartley, Paul Sanghera, Martin Forster, Mehmet Sen, Vinidh Paleri, Charles Fong, Dinos Geropantas, Devraj Srinivasan, Satya Garikipati, Rafael Moleron, Georgina Casswell, Eleanor Aynsley, Amy Ward, Lorcan O’Toole, Arafat Mirza, Charlotte Firth, Isla Humphreys, Tessa Fulton-Lieuw, Tom Roques, Paul Nankivell
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Patients with intermediate and high-risk oropharyngeal cancer (OPC) have poorer response to standard treatment and poorer overall survival compared to low-risk OPC. CompARE is designed to test alternative approaches to intensified
Externí odkaz:
https://doaj.org/article/330dec8870f14404b747cb77cc116ff3
Publikováno v:
Medicines, Vol 5, Iss 3, p 65 (2018)
Integrating immunotherapy, proton therapy and biological dose escalation into the definitive chemoradiation of oropharyngeal cancer poses several challenges. Reliable and reproducible data must be obtained in a timely fashion. However, despite recent
Externí odkaz:
https://doaj.org/article/ace8e4883096419c86c91a85b01e1468
Publikováno v:
Medicines, Vol 5, Iss 2, p 54 (2018)
Background: The effect of synchronous chemotherapy in squamous cell carcinoma of the head and neck (SCCHN) has been modelled as additional Biologically Effective Dose (BED) or as a prolonged tumour cell turnover time during accelerated repopulation.
Externí odkaz:
https://doaj.org/article/a4f67c0726074800a89b026f1563f92f
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 33(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d5b0eff29b8ca07aaaf31d27387cb47
https://pubmed.ncbi.nlm.nih.gov/33160791
https://pubmed.ncbi.nlm.nih.gov/33160791
Autor:
T. Roques, T. Fulton-Lieuw, M. Vreugdenhil, Paul Sanghera, Bernadette Foran, Mehmet Sen, Hisham Mehanna, M. Evans, Charles Fong, Christopher M. Nutting, M. Dalby, Gulnaz Iqbal, Andrew Hartley, H. Yang, H. Al Booz, L. O'Toole, N. Palaniappan, Janet A. Dunn
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 33(12)
AIMS The De-ESCALaTE study showed an overall survival advantage for the administration of synchronous cisplatin chemotherapy with radiotherapy in low-risk oropharyngeal cancer when compared with synchronous cetuximab. During the trial, a radiotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e595865dce0d9a9f9a73dd76152b3fa
https://pubmed.ncbi.nlm.nih.gov/34340917
https://pubmed.ncbi.nlm.nih.gov/34340917
Autor:
Mary Lei, Charles Fong, Christopher M. Nutting, Ifigenia Vasiliadou, Kate Newbold, Andrew Hartley, S.A. Bhide, Imran Petkar, Gemma Hegarty, Anthony Kong, Teresa Guerrero Urbano, Paul Sanghera, Andriana Michaelidou, Isla Leslie, J. Good, Kannon Nathan, Miguel Reis Ferreira, Van Ren Sim, Kevin J. Harrington, KH Wong, Omar Breik, Holly Baker
Publikováno v:
Cancers, Vol 13, Iss 1413, p 1413 (2021)
Cancers
Volume 13
Issue 6
Cancers
Volume 13
Issue 6
Simple Summary Nivolumab is an anti-PD-1 monoclonal antibody that has been approved in the management of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of progression within 6 months of platinum-based chemotherapy. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0129408e7bcead249d2e9ad317830249
https://www.mdpi.com/2072-6694/13/6/1413
https://www.mdpi.com/2072-6694/13/6/1413
Autor:
Mehmet Sen, M. Dalby, Hisham Mehanna, H. Al Booz, Janet A. Dunn, Christopher M. Nutting, Paul Sanghera, L. O'Toole, H. Yang, T. Fulton-Lieuw, Tom Roques, Charles Fong, B. Foran, Pankaj Mistry, Ann L. Hartley, M. Evans
Publikováno v:
Radiotherapy and Oncology. 152:S320-S321
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e010a1a08e42001d0f014feb8a4708f
https://doi.org/10.1016/s0167-8140(21)00595-8
https://doi.org/10.1016/s0167-8140(21)00595-8
Autor:
Dr Vijay Sawlani, Dr Nigel Davies, Dr Markand Patel, Mr Robert Flintham, Dr Charles Fong, Dr Geoff Heyes, Prof Garth Cruickshank, Dr Neil Steven, Prof Andrew Peet, Dr Andrew Hartley, Dr Helen Benghiat, Dr Sara Meade, Dr Paul Sanghera
BACKGROUND: Following stereotactic radiosurgery (SRS), brain metastases initially increase in size in up to a third of cases, suggesting treatment failure. Current imaging using structural MRI cannot differentiate between tumour recurrence and SRS-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59c008d8c50627c94433ca9bcf5b36b6
https://europepmc.org/articles/PMC6168849/
https://europepmc.org/articles/PMC6168849/
Publikováno v:
Medicines, Vol 5, Iss 3, p 65 (2018)
Medicines
Medicines
Integrating immunotherapy, proton therapy and biological dose escalation into the definitive chemoradiation of oropharyngeal cancer poses several challenges. Reliable and reproducible data must be obtained in a timely fashion. However, despite recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c742018587a8187c2599c8d4adce1005
http://www.mdpi.com/2305-6320/5/3/65
http://www.mdpi.com/2305-6320/5/3/65
Autor:
Robert Flintham, Helen Benghiat, Charles Fong, Vijay Sawlani, Andrew C. Peet, Sara Meade, Paul Sanghera, Nigel P. Davies, Garth Cruickshank
PurposeConventional MRI methods are insufficient to accurately differentiate between local tumour recurrence and radiation-induced necrosis. Advanced MRI techniques such as perfusion imaging, diffusion imaging and spectroscopy have individually been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cce4cdb253af78daaae650f567a6362
https://europepmc.org/articles/PMC5791684/
https://europepmc.org/articles/PMC5791684/